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data on depressive symptoms, hypochondriacal beliefs, life 
satisfaction, and sleep complaints were gathered in 15 aSAH 
patients and 17 healthy controls. HCCs of the previous 3 
months were assessed.  Results: aSAH patients had signifi-
cantly higher HCCs than healthy controls. In aSAH patients, 
higher HCCs were significantly associated with increased de-
pressive symptoms, hypochondriacal beliefs, lower life satis-
faction, and increased sleep complaints. Such significant as-
sociations were not found in healthy controls.  Conclusions: 
Our findings indicate that a dysregulation of HPA-AA is as-
sociated with some of the long-term impairments in psycho-
logical functioning and sleep in aSAH survivors. While the 
direction of association remained unclear, a dysregulated 
HPA-AA may be causally linked with the maintenance of 
poor psychological functioning and poor sleep. The overall 
findings should be considered in the planning of long-term 
treatment aimed at improving psychological functioning 
and sleep in aSAH patients.  © 2017 S. Karger AG, Basel 
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 Abstract 
 Background: Following an aneurysmal subarachnoid haem-
orrhage (aSAH), many patients report persistent deficits in 
psychological functioning, characterised by high levels of 
stress and symptoms of depression, low life satisfaction, 
along with poor sleep. Such deficits have been associated 
with altered saliva and serum cortisol levels due to a dys-
regulation of hypothalamic-pituitary-adrenal axis activity 
(HPA-AA). However, hair cortisol concentrations (HCCs) have 
not been assessed in this population, although this method 
allows a long-term insight into cortisol values. Therefore, the 
objective of this study was to compare HCCs in aSAH pa-
tients and healthy controls and to examine how HCCs are 
associated with perceived stress, psychological functioning, 
and sleep complaints.  Methods: In this cross-sectional study, 
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 Introduction 
 Aneurysmal subarachnoid haemorrhage (aSAH) is 
characterised by the rupture of a cerebral artery and con-
sequent bleeding into the area surrounding the brain 
known as the subarachnoid space  [1] . Although this form 
of stroke has a high morbidity and mortality, in past de-
cades improvements in neurosurgery and emergency 
treatment algorithms have increased the survival rate to 
65%  [2] . However, a large proportion of survivors contin-
ues to suffer from physical and psychological deficits fol-
lowing the initial recovery period  [3] . The aSAH itself, 
combined with the frequently persistent deficits experi-
enced in the aftermath, results in a severely impaired 
quality of life of aSAH survivors years after ictus  [4] .
 As regards the psychological functioning, aSAH survi-
vors reported increased anxiety levels  [5] , probably asso-
ciated with the fear of recurrent haemorrhage  [6] . Com-
pared to healthy controls, aSAH patients also experienced 
more frequent depressive symptoms  [7] , increased fa-
tigue  [8] , and a poorer sleep quality  [7] . Symptoms of de-
pression, fatigue, and poor sleep persisted up to 4 years 
after ictus  [9] , which explained why quality of life also 
remained low many months after surgery  [10] .
 Besides the anxiety of a next stroke, one explanation 
for the persistently impaired psychological functioning in 
aSAH survivors might be the possibility of a dysregula-
tion of hypothalamic-pituitary-adrenal axis activity 
(HPA-AA) after aSAH  [11] , with cortisol as main out-
come marker. While a downregulation of the adrenocor-
ticotropic hormone (ACTH), the precursor of cortisol, 
has been repeatedly shown, findings on the cortisol levels 
are less consistent.
 With regard to ACTH, an underactivity of the HPA-
AA has been documented in aSAH survivors: Tanriverdi 
et al.  [12] reported ACTH deficiencies in 23% of aSAH 
patients in the acute phase, and 14% 12 months after ic-
tus. Moreover, in a large register study with 417 aSAH 
patients the prevalence of hypopituitarism in the chronic 
phase (at least 5 months after the event) by laboratory 
values, physician diagnoses, and stimulation tests, was 35, 
36, and 70%, respectively, with decreased ACTH levels 
being the most frequent endocrine dysfunction in this 
group of patients  [13] . Finally, similar results were re-
ported in a meta-analysis with 19 studies and 1,137 aSAH 
patients, yielding hypopituitarism in 47% of patients in 
the chronic phase  [14] .
 As regards the cortisol secretion assessed in blood and 
saliva, prior research has provided mixed results. For in-
stance, Karaca et al.  [15] found that serum basal cortisol 
levels were significantly elevated 3 years after aSAH. 
However, Brand et al.  [7] found no statistically significant 
differences between aSAH patients (5–9 months after ic-
tus) and healthy controls with regard to the salivary cor-
tisol awakening response (CAR), neither for the area un-
der the curve with respect to increase (AUCi; represent-
ing the increase in cortisol secretion in relation to the first 
of the postwaking measurements) nor with respect to 
ground (AUCg; representing overall cortisol output). 
Furthermore, the CAR was neither related to patients’ 
psychological functioning nor to their subjective or ob-
jective sleep. By contrast, Gerber et al.  [16] observed that 
compared to healthy controls, aSAH patients (mean = 44 
months after ictus) had significantly higher salivary CAR 
as measured by the AUCi. However, aSAH patients also 
had descriptively lower overall cortisol output values, 
represented by the AUCg. Gerber et al. concluded that a 
disconnection between the AUCi and AUCg values was 
plausible, as the values represented differing aspects of 
HPA-AA (reactivity vs. total output)  [16] .
 In summary, previous research suggested that the 
HPA-AA was indeed affected in aSAH patients. Howev-
er, given the inconsistencies in the available literature, it 
remains unclear whether aSAH patients have lower or 
higher basal cortisol levels than healthy controls, and how 
exactly cortisol levels are related to other health out-
comes. In part, the inconsistencies found in prior re-
search can be attributed to the fact that salivary and plas-
ma cortisol levels represent single time point assessments 
and only reveal acute circulating cortisol levels or mean 
cortisol secreted over a relatively short period of time. 
Moreover, salivary and plasma cortisol are easily affected 
by temporary or transient disturbances in psychosocial 
stress on the day of measurement, subject to diurnal vari-
ations and affected by any food intake, smoking and 
physical activity that takes place shortly before sampling. 
By contrast, hair cortisol measurement has the potential 
to overcome these methodological difficulties associated 
with the assessment of long-term cortisol levels  [17, 18] . 
For instance, Stalder et al.  [19] showed that hair cortisol 
concentrations (HCCs) have a high intra-individual sta-
bility, with correlations of repeated assessments between 
2 months and 1 year ranging between 0.68 and 0.79. 
Therefore, hair cortisol assessments have become an in-
creasingly accepted approach in endocrinology and bio-
psychology during the last few years  [18] .
 To date, hair cortisol as a biomarker of HPA-AA has 
not been studied in aSAH patients. Therefore, the goal of 
the present study was twofold: first, to compare for the 
first time HCCs in aSAH patients and healthy controls; 
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second, to examine how HCCs are associated with per-
ceived stress, psychological functioning, and sleep com-
plaints, domains in which aSAH patients have frequently 
reported deficits, separately for aSAH patients and healthy 
controls.
 The following 2 hypotheses were formulated. Follow-
ing Dettenborn et al.  [20] and Van Uum et al.  [21] , our 
first hypothesis was that higher HCCs would be associ-
ated with poorer psychological functioning (including 
depressive symptoms, hypochondria, and life satisfac-
tion). Second, although Maurer et al.  [22] were unable to 
find significant associations between hair cortisol and ob-
jective sleep parameters in young children, we assumed 
that higher HCCs would be associated with poorer qual-
ity of sleep in aSAH survivors, because poor sleep and 
depressive symptoms are strongly correlated in aSAH pa-
tients  [16, 23] .
 Methods 
 Participants 
 The sample comprised 32 participants (22 women, 10 men; 
mean age = 57.4 years, SD = 10.7; mean BMI = 26.2, SD = 3.7). 
Fifteen participants (11 women, 4 men; mean age = 57.2 years,
SD = 8.9) were patients with aSAH and following neurosurgical 
or endovascular intervention. One patient had received coiling, 
and 14 underwent clipping. No patient presented with additional 
untreated aneurysms. The mean Glasgow Outcome Score was 
4.33 (SD = 0.6), indicating an ability to live independently but with 
some deficits. Five had a Fisher grade of 4, another 5 had a grade 
of 3, and 1 of 2. These data were not available for 4 patients. Five 
had a Hunt and Hess grade of 4, then 5 had a grade of 3, and 2 of 
2. This information was not available for 3 patients. The mean 
time spent in intensive care was 8.3 days (SD = 2.8). The mean 
time after intervention was 44 months (SD = 28.9; range 3–72 
months, median = 60 months, 25th percentile: 9 months, 75th 
percentile: 69 months).
 The second group consisted of 17 healthy controls (11 women, 
6 men; mean age = 59.8 years, SD = 10.8). To reduce bias, healthy 
controls were matched for age and sex. Accordingly, the 2 groups 
did not differ with regard to age,  F (1, 31) = 0.01,  p = 0.946, 
η 2 = 0.000, sex, χ 2 (1, 31) = 0.28,  p =  0.599, Φ = 0.092, and BMI, 
 F (1, 31) = 2.75,  p =  0.108, η 2 = 0.084. Use of medication tended to 
be more frequent among aSAH patients ( n =  12; 80%) than healthy 
controls ( n =  3; 25%), χ 2 (1, 31) = 3.69,  p =  0.055, Φ = 0.322. How-
ever, none of the participants indicated that they used corticoste-
roid medication.
 Study Design and Procedure 
 The design of this study was cross-sectional. Patients were eli-
gible if they were treated for aSAH at the Department of Neuro-
surgery at the University Hospital Basel, Switzerland, and were 
recruited during the consultation hours. Healthy controls were re-
cruited via online advertisements on local news websites. Those 
willing to participate in the study provided informed consent and 
were assured confidentiality of their responses prior to the data as-
sessment. Approval for the study was obtained from the local eth-
ical committee (EKNZ, approval No. 61/12). The study was con-
ducted in accordance with the ethical principles described in the 
1964 Declaration of Helsinki. Power analysis was used to establish 
the minimal sample size to find large correlations ( r = 0.50–0.60). 
Using G * Power Software 3 (alpha error = 0.05, power = 0.80), be-
tween 13 ( r = 0.60) and 21 ( r = 0.50) aSAH patients and healthy 
controls were needed.
 All data assessments took place at the participants’ homes be-
tween April 2012 and April 2013 and were carried out by a trained 
research assistant. Previously, data from this study had been pub-
lished indicating that aSAH patients reported poorer subjective 
sleep and more sleep-related dysfunctional cognitions and hypo-
chondriacal beliefs than healthy controls  [16] . However, data on 
hair cortisol have not been published elsewhere.
 Instruments 
 Depressive Symptoms 
 The Beck Depression Inventory was used to assess the severity 
of depressive symptoms  [24] . It consists of 21 items scaled from 0 
to 3 including a range of affective, behavioural, cognitive, and so-
matic symptoms that are indicative of unipolar depression (e.g., “I 
am so unhappy/sad that I can’t stand it”). Possible scores ranged 
from 0 to 63 with higher scores indicating more depressive symp-
toms.
 Hypochondriacal Beliefs 
 The 14-item Whiteley Index was used to assess hypochondria-
cal beliefs (e.g., “Are you bothered by many aches and pains?”) 
 [25] . Answers were “yes” (=1) or “no” (=0), with higher sum scores 
reflecting a greater inclination to overestimate bodily sensations 
and pain.
 Satisfaction with Life 
 The 5-item Satisfaction with Life Scale was used to obtain an 
overall judgement of respondents’ satisfaction with life  [26] . An-
swers are given on a 7-point Likert-type scale (e.g., “In most ways, 
my life is close to my ideal”). The items were summed to generate 
a composite score.
 Sleep Complaints 
 The 7-item Insomnia Severity Index was administered to assess 
participants’ subjective sleep complaints  [27] . The items refer in 
part to the DSM-IV criteria for insomnia by measuring difficulty 
in falling asleep, difficulties maintaining sleep, early morning 
awakening, increased daytime sleepiness, low daytime perfor-
mance, low satisfaction with sleep, and worrying about sleep. Pos-
sible answers range from 0 (not at all) to 4 (very much), with high-
er sum scores reflecting higher insomnia.
 Hair Cortisol 
 HCC was assessed using samples of hair, approximately 3 mm 
in diameter, which are cut close to the scalp of the study partici-
pants. The 3 cm of hair closest to the scalp are tested for cortisol 
concentration and provide a value encompassing the previous 3 
months. In some cases, participants with particularly short hair do 
not provide sufficient material for analysis; this was the case with 
3 participants from the control group, who were subsequently ex-
cluded from the analyses. The samples were analysed at the bio-
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chemical laboratory of the University of Dresden, Germany, as de-
scribed in the protocol by Kirschbaum et al.  [28] . To summarise, 
each individual hair sample is washed twice with 2.5 mL of isopro-
panol for 3 min, dried over a 12-h period, and then powdered in a 
Retsch ball mill at 30.0 Hz, for a period of 5 min; 25 mg of the 
powdered hair is then transferred into a 2-mL cryovial. Then 1.5 
mL of pure methanol is added to the vial, which is rotated slowly 
for 45 min, in order for steroids to be extracted. The sample is then 
centrifuged at 10,000 r.p.m. for a period of 3 min (relative centrif-
ugal force = 10,080  g ). One millilitre of clear supernatant is placed 
in a new vial, and the methanol is evaporated using a steady stream 
of nitrogen (60  °  C) until the sample is dry; 0.4 mL of commercial-
ly available phosphate buffer (IBL-International, Hamburg, Ger-
many) containing 0.1% bovine serum albumin, at a pH of 7.1, is 
added to the vial, which is then vortexed for 15 s. Cortisol is deter-
mined by analysing 80 μL of the reconstituted sample by a com-
mercially available immunoassay (CLIA, IBL-International, Ham-
burg, Germany). In accordance with the study of Skoluda et al. 
 [29] , the minimal amount of powdered hair used in this study was 
25 mg, instead of 50 mg in the protocol of Kirschbaum et al.  [28] . 
Intra- and interassay coefficients of variance were below 10% in 
the present study.
 Statistical Analyses 
 None of the participants had missing values. Differences in 
HCCs, psychological functioning, and sleep between aSAH pa-
tients and healthy controls were examined with univariate analy-
ses of variances (ANOVAs). Differences between aSAH patients 
and healthy controls with regard to stress, psychological func-
tioning, and sleep have been described elsewhere  [16] . Bivariate 
associations between hair cortisol levels, stress, psychological 
functioning, and sleep were examined via Pearson’s product mo-
ment correlations, separately for aSAH patients and healthy con-
trols. Following Cohen  [30] , effect sizes for ANOVAs (partial  η 2 ) 
were considered as follows: small = 0.01 >  η 2 < 0.059, medium = 
0.06 >  η 2 < 0.139, or large =  η 2  ≥ 0.14. Cohen’s criteria were also 
used to interpret correlations (e.g., small: 0.10–0.30; medium: 
0.30–0.50; large: >0.50)  [30] . The level of probability was set at
 p  < 0.05 across all analyses. All statistics were performed with 
SPSS ® 22.0 (IBM Corporation, Armonk, NY, USA) for Apple 
MacIntosh ® .
 Results 
 Descriptive Statistics 
 The descriptive statistics for the total sample are pre-
sented in  Table 1 .  Table 1 also shows that the internal con-
sistencies for all indicators related to psychological func-
tioning and subjective sleep were adequate.
 Differences in Hair Cortisol, Psychological 
Functioning, and Sleep between aSAH Patients and 
Healthy Controls 
 HCCs were significantly higher in aSAH patients com-
pared to healthy controls,  F (1, 28) = 5.04,  p < 0.05,  η 2 = 
0.157 (aSAH: mean = 4.24 nmol/L, SD = 2.91; healthy 
controls: mean = 2.39 nmol/L, SD = 1.26). Moreover, 
aSAH patients perceived more depressive symptoms than 
healthy controls,  F (1, 28) = 4.75,  p < 0.05,  η 2 = 0.149 
(aSAH: mean = 8.50, SD = 6.65; healthy controls: mean = 
4.27, SD = 3.41), reported higher hypochondriacal beliefs, 
 F (1, 28) = 6.72,  p < 0.05,  η 2 = 0.199 (aSAH: mean = 4.00, 
SD = 3.44; healthy controls: mean = 1.60, SD = 0.99), and 
exhibited more sleep complaints,  F (1, 28) = 10.04,  p < 
0.01,  η 2 = 0.271 (aSAH: mean = 8.64, SD = 5.15; healthy 
controls: mean = 3.93, SD = 2.49). No significant group 
differences were found with regard to satisfaction with 
life,  F (1, 28) = 1.60,  p = 0.22,  η 2 = 0.056 (aSAH: mean = 
24.93, SD = 8.16; healthy controls: mean = 28.27, SD = 
5.96).
 Correlations between Hair Cortisol and Psychological 
Functioning 
 In aSAH patients, higher HCCs were significantly as-
sociated with increased depressive symptoms, hypochon-
driacal beliefs, and with lower life satisfaction ( Table 2 ). 
The scatterplot shown in  Figure 1 suggests that the statis-
 Table 1.  Descriptive statistics of all study variables
Mean ± SD α (items)  Range Skew Kurtosis
potential actual
Hair cortisol concentration, nmol/L 3.28 ± 1.80 – 0+ 0.74 – 10.38 1.80 2.99
Depressive symptoms (BDI) 6.47 ± 5.48 0.87 (21) 0 – 63 0 – 26 1.56 3.83
Hypochondriacal beliefs (WI) 3.13 ± 3.93 0.78 (14) 0 – 56 0 – 19 2.68 8.35
Satisfaction with life (SWLS) 26.59 ± 7.00 0.93 (5) 5 – 35 5 – 35 –1.41 1.95
Sleep complaints (ISI) 5.91 ± 4.50 0.83 (7) 0 – 28 0 – 17 0.90 0.07
α = Cronbach’s alpha. n = 32. BDI, Beck Depression Inventory; WI, Whiteley Index; SWLS, Satisfaction with 
Life Scale; ISI, Insomnia Severity Index.
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tically significant correlation between patients’ HCCs 
and their depressive symptoms was not due to the impact 
of a single outlier. Similar patterns of results were found 
for all other indicators of psychological functioning.
 In healthy controls, none of the correlations were sig-
nificant. Descriptively, however, higher HCCs tended to 
be associated with fewer psychological symptoms ( r = 
–0.08 to –0.40,  p = ns).
 Correlations between Hair Cortisol and Sleep 
 In aSAH patients, higher HCCs were significantly as-
sociated with increased sleep complaints ( Table  2 ). In 
contrast, in healthy controls, no significant associations 
existed between participants’ HCCs and their subjective 
sleep. However, descriptively, higher HCCs were associ-
ated with fewer subjective sleep complaints ( r = –0.26,
 p = ns).
 Discussion 
 The key findings of the present study are that aSAH 
patients had higher hair cortisol levels than healthy con-
trols. Moreover, in the aSAH group, statistically signifi-
cant associations existed between increased HCCs and 
impaired psychological functioning and sleep, while such 
associations were not observed in healthy controls. In 
many respects, this study explored unknown territory. To 
the best of our knowledge, no research has been published 
so far on hair cortisol levels in aSAH patients compared 
to healthy controls, and few studies have assessed the de-
gree to which high hair cortisol levels are associated with 
stress and psychological functioning in clinical and non-
clinical populations. Thus, the present study expands 
upon the current literature in an important way, in that 
we were able to show that patients with aSAH reported 
poorer subjectively assessed psychological functioning 
and more sleep complaints  [16] , which at the physiologi-
cal level were reflected by statistically significantly higher 
HCCs. Higher HCCs, in turn, are believed to reflect a 
chronic upregulation of HPA-AA.
 An underlying cause of irregularities in endocrine dys-
function in patients who have undergone aSAH and sub-
sequent medical intervention can be damage to regions of 
the brain involved in HPA axis regulation  [31, 32] . These 
irregularities have been shown to persist up to 24 months 
after ictus  [33] . Some studies have suggested that this is 
 Table 2.  Correlations between hair cortisol and psychological variables, separately for aSAH patients and healthy 
controls
1 2 3 4 5
1 Hair cortisol concentration, nmol/L – –0.40 –0.13 –0.10 –0.26
2 Hypochondriacal beliefs (WI) 0.62* – 0.20 0.07 0.40
3 Depressive symptoms (BDI) 0.56* 0.74*** – –0.39 0.27 
4 Satisfaction with life (SWLS) –0.65* –0.65** –0.72** – –0.29
5 Sleep complaints (ISI) 0.54* 0.18 0.56* –0.26 –
 Above the diagonal: healthy controls (n = 17). Below the diagonal: aSAH patients (n = 15). *** p < 0.001,
** p < 0.01, * p < 0.05. For abbreviations, see Table 1.
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 Fig. 1. Scatterplot illustrating the bivariate relationship between 
hair cortisol concentrations and depressive symptoms in aSAH pa-
tients. 
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more likely following clipping, as opposed to coiling  [34] ; 
in the present study, 14 of the 15 patients had undergone 
clipping. For instance, damage to the hippocampus, 
which can be the result of clipping, can lead to alterations 
in cortisol secretion  [35] . However, in the present study, 
there was no suggestion that major areas of the hypotha-
lamic-pituitary system were damaged. Consequently, we 
are unable to draw conclusions about the influence of 
particular haemorrhage locations on HCCs.
 Given the absence of previous studies, we did not for-
mulate a specific hypothesis as to whether aSAH patients 
would have higher or lower HCCs compared to healthy 
controls. In the present study, we observed higher HCCs 
in the aSAH group. Accordingly, the present data are at 
odds with studies showing that patients with aSAH have 
suffered from hypopituitarism  [14, 36] and tended to 
have a lower morning overall cortisol output  [16] . How-
ever, previous studies have also shown that compared to 
healthy controls, aSAH patients had a higher CAR as 
measured by the AUCi  [16] . Moreover, serum basal cor-
tisol and ACTH levels were found to significantly in-
crease from the first to the third years after surgical inter-
vention  [15] . Thus, the elevated HCCs might be explained 
by the fact that the mean time since surgery amounted to 
44 months in the present study. Unfortunately, the pres-
ent data do not allow a determination of the cause of the 
high HCCs found in aSAH patients. Thus, once these 
findings have been confirmed in larger samples, a next 
step could be to examine whether the elevated HCCs in 
aSAH survivors are attributable to ACTH dependent or 
ACTH independent sources  [37] . Nevertheless, the ele-
vated HCCs in aSAH patients are critical as increased 
HCCs have been shown to constitute a risk factor for car-
diovascular diseases  [38] , diabetes mellitus  [39] , increased 
BMI and obesity  [40] , and the occurrence of metabolic 
syndrome  [41] . Finally, as reported in a previous paper 
 [16] , aSAH patients reported significantly higher depres-
sive symptoms, hypochondriacal beliefs, and sleep com-
plaints than healthy controls.
 Two hypotheses were formulated. Our first hypothesis 
was that higher HCCs would be associated with poorer 
psychological functioning, and the data did confirm this 
notion, though specifically in aSAH patients, but not in 
healthy controls. Importantly, in aSAH patients, most 
correlations between HCCs and psychological function-
ing were of strong magnitude (rs between 0.54 and –0.65), 
and the inspection of the scatterplots indicated that single 
outliers did not affect the correlations. Moreover, the 
same pattern of results was found across all indicators of 
psychological functioning including depressive symp-
toms, hypochondriacal beliefs, and life satisfaction. The 
close link between increased HCCs and poor psychologi-
cal functioning accords well with previous research show-
ing that higher HCCs have been observed in individuals 
suffering from depression  [20] and severe chronic pain 
 [21] . The fact that HCCs were significantly associated 
with psychological functioning in aSAH patients, and not 
in healthy controls, accords well with a study on healthy 
young adults  [42] , in which higher HCCs were associated 
with lower depressive symptoms. However, our findings 
add to the existing literature by providing preliminary ev-
idence that high HCC levels can be used as a biomarker 
for poor psychological functioning among aSAH popula-
tions. This finding is important as researchers were not 
able to correlate assessments of pituitary hormone dys-
regulation with the outcomes of aSAH patients in previ-
ous studies  [36] .
 Our second hypothesis was that higher HCCs would 
be associated with more frequent sleep complaints  [16, 
23] . The data supported this hypothesis for aSAH pa-
tients, but not for healthy controls. While heightened ac-
tivity of the HPA axis has been associated with sleep com-
plaints  [43] , it has to date not been conclusively estab-
lished whether HPA axis overactivity precedes sleep 
complaints or occurs as a result of the emotional stress of 
poor sleep  [44] .
 While the present study provided novel insights into 
the association between HCCs, psychological function-
ing, and sleep in aSAH versus healthy controls, the cur-
rent results must be considered in light of certain limita-
tions. First, the relatively small sample size made it diffi-
cult to detect statistically significant correlations, and 
precluded separate analyses for male and female partici-
pants. Nevertheless, results showed medium to large ef-
fect sizes, which do not rely on sample sizes. Second, pa-
tients were recruited at different time points following 
surgery. However, ANOVAs comparing participants be-
low versus above the median of posttreatment time re-
vealed no influence on the existence or severity of deficits 
in the measured parameters or with regard to HCC (data 
not shown). Accordingly, the increased hair cortisol lev-
els in aSAH patients appear to be due to the event per se 
and do not represent a cumulative effect over time. Third, 
the cross-sectional study design did not allow conclusions 
to be drawn regarding a possible causal relationship be-
tween HCCs, psychological functioning, and sleep. 
Fourth, medication intake prior to the beginning of the 
study was not recorded. It is therefore possible that the 
hair samples may have been affected by medications 
which influence cortisol secretion. However, as noted in 
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the text, participants provided detailed information about 
their medication intake at the moment of the data assess-
ment. The inspection of this data revealed that no par-
ticipant consumed corticosteroid medication. Moreover, 
the medications consumed have been analysed in light of 
their potential effects on the activity of the HPA axis and 
cortisol secretion. In the aneurysm group, 1 patient took 
the diabetes medication metformin. While Haugen  [45] 
notes that metformin has been reported to affect thyroid 
function, this finding has not been confirmed by multiple 
studies and requires further investigation. Moreover, no 
direct effects upon cortisol secretion have been docu-
mented  [46] . Additionally, 1 patient took 2 forms of an-
tidepressant (escitalopram and mirtazapine), which both 
have been shown to reduce salivary cortisol  [47, 48] . 
While purely hypothetical, as our findings show increased 
cortisol levels amongst aSAH patients, we feel that the in-
take of these medications by 1 patient is not likely to have 
exaggerated our results. In the control group, 1 partici-
pant took medication for high cholesterol (Crestor), and 
1 took hormone replacement therapy. In the  comprehen-
sive list of medications of Granger et al.  [49] ,  which, by 
their mechanism of action, could influence salivary cor-
tisol, these forms of medication are considered. However, 
Rosuvastatin, the active ingredient in Crestor, taken 
alone, has not been shown to affect plasma cortisol levels 
 [50, 51] . Regarding the hormone replacement therapy, 
this was a combination of oestrogen and progesterone, 
which has not been shown to significantly increase plas-
ma cortisol concentration, in comparison to oestrogen 
alone  [52] . Fifth, we acknowledge that while we used a 
standardised and validated tool to assess self-reported 
symptoms of depression, this instrument does not corre-
spond to a diagnostic tool to assess depression as defined 
in the international classification systems such as the 
ICD-10  [53] . Because the HPA system is usually dis-
turbed during an acute major depressive episode  [54] , we 
were not able to control for this confounding factor of 
altered HPA regulation.
 Conclusion 
 The findings indicate that a dysregulation of HPA-AA 
may explain some of the long-term deficits experienced 
by aSAH survivors. However, these findings need to be 
replicated in future research, and more knowledge is re-
quired as to how hair cortisol levels change over the 
course of time in aSAH survivors. Finally, our findings 
suggest that HPA axis abnormalities should be taken into 
account in the planning of long-term treatment in aSAH 
survivors.
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